Wu Larry, Salti Giovanni, Cotofana Sebastian, Vercesi Franco
iCare Medical Centre, Singapore, Singapore.
Istituto Medico Medlight, Florence, Italy.
J Cosmet Dermatol. 2025 Jun;24(6):e70262. doi: 10.1111/jocd.70262.
Innovative use of a point-of-care ultrasound (POCUS) device facilitates the diagnosis and management of potential challenges associated with Ellanse treatment. Our case series of 6 patients illustrates the effectiveness of POCUS in managing challenges associated with Ellanse treatment. Ultrasound analysis is performed in all 6 patients, and management decisions are guided by ultrasound findings.
Our case series of 6 patients (A, B, C, D, E & F) consists of Ellanse-treated patients. They presented problems associated with (1) facial overfilling, (2) diagnostic challenges, (3) underfilling requiring POCUS-guided treatment, (4) confirmation of nodule dissolution, and (5) pretreatment vascular assessment.
Patients A and B presented with complaints of facial overfilling, and ultrasound analysis attributed the overfilling to previous autologous fat grafting and hyaluronic acid filler treatments respectively. Patient C complained of facial cheekbone prominence after receiving 26 mL of Ellanse in her entire face over 3 years. The patient was reassured that her cheek prominence was secondary to neocollagenesis following ultrasound analysis and refused further intervention. Patient D had successful dissolution of a nodule associated with Ellanse, and this was confirmed with photographs and POCUS imaging. Patient E had underdevelopment of collagen in the left midcheek following initial Ellanse treatment 3 months ago. 0.2 mL of additional Ellanse was injected with a 25G cannula under POCUS guidance to the left cheek with satisfactory correction. Patient F had three previous sessions of Ellanse treatments. She underwent vascular anatomy analysis with an ultrasound Doppler mode prior to the fourth Ellanse treatment. The presence of dense neocollagenesis following Ellanse can alter vascular patterns. A preprocedural analysis is recommended in planning subsequent treatment.
Our limited case series of 6 patients provides useful insights into the effectiveness of POCUS as the initial imaging modality of choice when managing Ellanse-treated patients. POCUS imaging provides valuable diagnostic information (Patient A, B, C and D) and therapeutic purposes such as POCUS guided injection and pretreatment assessment (Patient D and E). POCUS can be the initial imaging modality of choice as it is convenient and allows clinical management to be made based on imaging findings.
即时超声（POCUS）设备的创新应用有助于诊断和处理与Ellanse治疗相关的潜在难题。我们的6例患者病例系列说明了POCUS在处理与Ellanse治疗相关难题方面的有效性。对所有6例患者均进行了超声分析，并根据超声检查结果做出管理决策。
我们的6例患者（A、B、C、D、E和F）病例系列均为接受Ellanse治疗的患者。他们出现了与以下情况相关的问题：（1）面部填充过度；（2）诊断难题；（3）需要POCUS引导治疗的填充不足；（4）结节溶解的确认；（5）治疗前血管评估。
患者A和B主诉面部填充过度，超声分析分别将填充过度归因于先前的自体脂肪移植和透明质酸填充剂治疗。患者C在3年内在全脸注射了26 mL Ellanse后，抱怨面部颧骨突出。经超声分析后，患者被告知其脸颊突出是新胶原形成的结果，并拒绝了进一步干预。患者D成功溶解了与Ellanse相关的结节，这通过照片和POCUS成像得到了证实。患者E在3个月前首次接受Ellanse治疗后，左脸颊中部胶原蛋白发育不足。在POCUS引导下，使用25G套管针向左脸颊额外注射了0.2 mL Ellanse，矫正效果令人满意。患者F之前接受过3次Ellanse治疗。在第4次Ellanse治疗前，她使用超声多普勒模式进行了血管解剖分析。Ellanse治疗后出现的致密新胶原形成会改变血管模式。建议在规划后续治疗时进行术前分析。
我们仅6例患者的病例系列为POCUS作为管理接受Ellanse治疗患者的首选初始成像方式的有效性提供了有用的见解。POCUS成像提供了有价值的诊断信息（患者A、B、C和D）以及治疗用途，如POCUS引导注射和治疗前评估（患者D和E）。POCUS可以作为首选的初始成像方式，因为它方便且能根据成像结果进行临床管理。
